Clinical trial
Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With…
NCT00318643 · Halozyme Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00318643 |
|---|---|
| Title | Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer |
| Official title | A Phase 1-2a, Multicenter, Open-Label, Multiple Dose, Safety, Tolerability, and Pharmacokinetic Study of Recombinant Human Hyaluronidase (Chemophase®) in Combination With Mitomycin in Patients With Non-Muscular-Invasive Bladder Cancer |
| Lead sponsor | Halozyme Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Drug |
| Interventions | Mitomycin C, Chemophase |
| Enrollment | 27 |
| Start date | Mar 30, 2006 |
| Primary completion | Aug 11, 2009 |
| Completion | Aug 11, 2009 |
| First posted | Apr 27, 2006 |
| Last update posted | Oct 29, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: